<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02993640</url>
  </required_header>
  <id_info>
    <org_study_id>EPN879-13</org_study_id>
    <nct_id>NCT02993640</nct_id>
  </id_info>
  <brief_title>Optimization of Hepatic Hemodynamics During Liver Surgery</brief_title>
  <official_title>Effects of Vasopressin and Nitroglycerine in Combination on Splanchnic Blood Flow, and on Hepatic and Portal Venous Pressures in Liver Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if vasopressin and nitroglycerin in combination
      will affect hepatic hemodynamics, in the setting of liver surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients in this study (undergoing elective liver resection) will be anesthetized
      according to routine practice in our hospital. A radial arterial catheter and a central
      venous catheter will be inserted, as well as a femoral arterial catheter for Picco
      monitoring. After the dissection phase, catheters will be inserted in the portal and hepatic
      veins by the surgeon. Base line data (HR, CVP, MAP, CO from thermodilution, portal and
      hepatic venous pressure, blood gases from radial artery, vena cava superior, hepatic vein and
      portal vein) will be obtained twice, with 10 minutes of steady state in between. An infusion
      of vasopressin 4,8 U/h will then be started and continued for 20 minutes. Data will be
      collected again, and an infusion of nitroglycerine (to a target of MAP 60 mmHg) will be
      added. After 5 minutes of steady MAP 55-65, the last set of data is collected. 12 Patients
      will be recruited, and the total data collection is estimated to be completed and assessed
      after six to nine months.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">March 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Portal and hepatic venous flow after vasopressin and nitroglycerine infusion</measure>
    <time_frame>six - nine months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pressure in the hepatic and portal veins after vasopressin and nitrovasopressin infusion</measure>
    <time_frame>six - nine months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>lactate in the splanchnic circulation</measure>
    <time_frame>six-nine months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Portal Blood Pressure</condition>
  <condition>Liver Surgery</condition>
  <condition>Hepatic Hemodynamics</condition>
  <arm_group>
    <arm_group_label>vasopressin + nitro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vasopressin + nitroglycerin in simultaneous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vasopressin + nitro</intervention_name>
    <description>vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.</description>
    <arm_group_label>vasopressin + nitro</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients within ASA-class I-II scheduled for open liver resection

        Exclusion Criteria:

          -  ASA-class III and IV, more than 2 medications for hypertension, BMI &gt; 35, technical
             difficulties with insertion av catheters, extensive surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven-Erik Ricksten, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2016</study_first_submitted>
  <study_first_submitted_qc>December 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2016</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Ellinor Wis√©n</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>vasopressin</keyword>
  <keyword>nitroglycerine</keyword>
  <keyword>portal pressure</keyword>
  <keyword>portal flow</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plans of sharing IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

